Lilly overtakes rival J&J in market cap to become world’s most valuable drugmaker
Eli Lilly and Co. shares have soared 57% over the past 52 weeks, buoyed in part by sales of its diabetes drug Mounjaro, which the company is also preparing to seek approval to market for obesity.